Mast Therapeutics, Inc. (NYSE MKT: MSTX) today provided an update on the status of EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease. Consistent with prior guidance, the Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback